In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action …

V Trebosc, B Schellhorn, J Schill… - Journal of …, 2020 - academic.oup.com
Background Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …
被引用次数：29 相关文章

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action …

V Trebosc, B Schellhorn, J Schill… - The Journal of …, 2020 - europepmc.org
Background Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …
[HTML] nih.gov

[HTML][HTML] In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of …

V Trebosc, B Schellhorn, J Schill… - Journal of …, 2020 - ncbi.nlm.nih.gov
Background Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action …

V Trebosc, B Schellhorn, J Schill, V Lucchini, J Bühler… - 2020 - cabidigitallibrary.org
Background: Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …
[PDF] archive.org

[PDF][PDF] In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of …

M Bourotte, JJ Butcher, M Gitzinger, S Lociuro… - scholar.archive.org
Background: Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action …

V Trebosc, B Schellhorn, J Schill… - The Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …
[PDF] semanticscholar.org

[PDF][PDF] In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of …

M Bourotte, JJ Butcher, M Gitzinger… - J Antimicrob …, 2020 - pdfs.semanticscholar.org
Background: Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …
[PDF] oup.com

[PDF][PDF] In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of …

V Trebosc, B Schellhorn, J Schill… - Journal of …, 2020 - academic.oup.com
Background Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action …

V Trebosc, B Schellhorn, J Schill, V Lucchini… - The Journal of …, 2020 - folia.unifr.ch
OBJECTIVES To determine rifabutin in vitro activity and resistance mechanisms in a large
panel of A. baumannii isolates. METHODS Two hundred and ninety-three carbapenem …
[PDF] researchgate.net

[PDF][PDF] In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of …

M Bourotte, JJ Butcher, M Gitzinger, S Lociuro… - researchgate.net
Background: Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …